European nanotechnology experts studied best practices and methods at the Nanotechnology Characterization Laboratory (NCL), and shared their own knowledge with NCL scientists before heading home to kick-start an NCL-like operation in Europe.
The European Union Nanomedicine Characterisation Laboratory (EUNCL) plans to open for business in mid-2016 with funding from the European Commission and support from the NCL and organizations in France, Germany, Ireland, Italy, Norway, Switzerland, and the United Kingdom.
“No reason to reinvent the wheel,” said Luigi Calzolai, Ph.D., of the Joint Research Centre of the European Commission in Italy. He and his colleagues spent two weeks onsite learning from NCL’s 12 years of experience in developing and implementing standards-based processes for characterizing nanoparticles for use in precision medicines against cancer.
“The European Union wants to bridge gaps in nanomedicine research and build a pan-European infrastructure for its characterization and translational opportunities,” said Adriele Prina-Mello, Ph.D., of Trinity College Dublin. Prina-Mello is also an executive board member and chair of the Toxicology, Characterisation and Regulation Issues working group at the European Technology Platform for Nanomedicine.
European Nanomedicine Characterisation Laboratory (EUNCL)